News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC seeking feedback on High Cost Medicines

Monday, December 18, 2006

PHARMAC seeking feedback on High Cost Medicines

PHARMAC is seeking public submissions on a review of how high cost medicines are assessed and funded.

High Cost Medicines are generally regarded as those treatments costing more than $20,000 per patient per year. This is an important issue for New Zealand given the significant cost of some medicines (some of which only treat small numbers of people) and potentially even higher costs for new medicines in the future.

PHARMAC is posting the consultation paper, and background information, on its website (

Acting Chief Executive Matthew Brougham says the fundamental question PHARMAC is seeking to answer is whether high cost medicines should be assessed differently to other medicines, when considering them for funding.

“This issue – how best to assess and fund high cost medicines - is not unique to PHARMAC; it is a challenge to all medicines funding bodies worldwide, and a hotly debated topic in international medical journals,” Matthew Brougham says

“PHARMAC currently uses the same assessment framework for all medicines, and the question we are posing is whether high cost medicines should be assessed differently to other medicines,” Matthew Brougham says.

“The expert views are thought-provoking and cover a wide range of issues. Having considered those views, our preliminary conclusion is that there are no persuasive arguments for treating the funding of high cost medicines differently to other medicines.”

“In other words, while there are some alternative approaches that can be used, the analytical tools and decision making framework that PHARMAC currently uses are appropriate. We now want to test this preliminary view publicly.”

PHARMAC has sought views on the issue from both New Zealand and international expert commentators. Initial reports were commissioned from an international medical ethicist and a respected health economist. These reports were then commented on by nine reviewers representing consumer, Maori, clinical, economic and philosophical perspectives. All of these reports are being made publicly available, in order to make the consultation process as open and well-informed as possible.

Matthew Brougham says the release of the Government’s medicines strategy discussion document last week acknowledges the importance of the high cost funding issue and PHARMAC’s ongoing work in this area.

Feedback is being sought by 5 March 2007.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>